The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sequential use of targeted therapies for metastatic renal cell carcinoma: A physician survey and chart review of community oncology practices in the United States.
Nicholas J. Vogelzang
Honoraria - Novartis
Research Funding - Novartis
James E. Signorovitch
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - I am an employee of Analysis Group, which received research funding from Novartis
Research Funding - I am an employee of Analysis Group, which received research funding from Novartis; Novartis
Peggy L. Lin
Employment or Leadership Position - Analysis Group
Consultant or Advisory Role - Analysis Group; I am an employee of Analysis Group, which received research funding from Novartis; I am an employee of Analysis Group, which received research funding from Novartis; Novartis
Research Funding - I am an employee of Analysis Group, which received research funding from Novartis; Novartis
Zhimei Liu
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Kenneth W. Culver
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Jeffrey A. Scott
No relevant relationships to disclose
Sumanta Kumar Pal
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Eric Jonasch
Consultant or Advisory Role - AVEO; AVEO; GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Pfizer; Pfizer
Research Funding - Bristol-Myers Squibb; Bristol-Myers Squibb; GlaxoSmithKline; GlaxoSmithKline; Novartis; Novartis; Pfizer; Pfizer